ArticleClinical and experimental nephrology2026
Prevalence, risk factors, and the screening value of basal cortisol for adrenal insufficiency after corticosteroid therapy in children with idiopathic nephrotic syndrome.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildren with idiopathic nephrotic syndrome (INS) receive prolonged glucocorticoids that can suppress the hypothalamic-pituitary-adrenal (HPA) axis and cause adrenal insufficiency (AI). We estimated the prevalence, risk factors, and basal-cortisol screening performance of biochemical AI in children with INS in remission and off corticosteroids.
methodsIn this single-centre cross-sectional study, 138 children with INS, off corticosteroids for ≥3 months after ≥2 weeks of full-dose prednisolone, underwent a standard-dose ACTH stimulation test (25 IU intramuscular Acton Prolongatum). Peak cortisol <500 nmol/L (18 µg/dL) defined AI.
resultsBiochemical AI occurred in 26/138 children (18.8%). Low basal cortisol (< 138 nmol/L) occurred in 18 (13.0%) but captured only 12 of 26 cases. Suppression did not differ by NS subtype (p = 0.392). Suppressed children were older at enrolment (median 129 vs 97 months; p = 0.044) and had ≈31% lower basal cortisol (159.0 vs 230.5 nmol/L; p < 0.001). Basal cortisol moderately discriminated AI (AUC 0.798; negative predictive value 92.9% at an exploratory cut-off of 186.5 nmol/L). Prevalence declined with time off steroids (23.1%, 21.2%, and 13.2% at 3-6, 6-12, and >12 months; p = 0.400). Exploratory multivariable analysis, limited by few events, identified no significant predictors. All five children with peritonitis-related hypotension had AI.
conclusionsBiochemical AI affects one in five children with INS after prolonged corticosteroid therapy and may persist beyond one year. Basal morning cortisol may serve as an initial screen, but this exploratory threshold requires validation in independent cohorts. Dynamic testing and stress-dose preparedness remain important.
Indexed as
Identifiers
42801413What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.